Related Articles
Prognosis and endocrine therapy selection for patients with low hormone receptor‑positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China
Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm
Predictive value of phosphorylated mammalian target of rapamycin for disease‑free survival in breast cancer patients receiving neoadjuvant chemotherapy
Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia